Abstract: A 4H-1-benzopyran-4-one derivative of the general formura ?1!, ##STR1## or a salt thereof exerts excellent effects on immunomodulation and cell adhesion inhibition, and is further expected to have the effect of relieving autoimmune diseases at a level comparable to that of steroids. Thus, the compound of the general formula ?1! is useful in the teatment and prevention of autoimmune diseases fundamentally caused by immunopathy or unusually accelerated cell adhesion, for example, chronic rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease,polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, serious adynamia, ulcerative colitis, chronic active hepatitis, autoimmune hemolytic anemia idiopathic thrombocytopenic purpura and the like.

Abstract: The object of the present invention is to provide a fuel treating device having a small pressure loss and a high contacting efficiency between fuel and fuel treating material. To attain said object, fuel treating material(s) 16, 26, 36 is(are) movably arranged in a fuel treating container 12, 22, 32 and said fuel treating material(s) 16, 26, 36 is(are) moved by flow pressure of the fuel to improve the contacting efficiency between said fuel treating material(s) 16, 26, 36 and the fuel and treat fuel by contacting with said fuel treating materials 16, 26, 36.

Abstract: This invention relates to a 4H-1-benzopyran-4-one derivative represented by the formula: ##STR1## or a salt thereof, a process for producing the same and a pharmaceutical composition comprising the same as active ingredient.

Abstract: Process for the preparation of tropane alkaloids, more particularly of N-acyl-dehydronortropinones, dehydrotropine and tropine. The compounds can be prepared by cyclocoupling N-acyl-pyrrole with .alpha.,.alpha.'-halogenoketone in the presence of a reducing agent and, if necessary, subjecting the resulting N-acyl-dehydronortropinone to either partial reduction and then stereo-selective reduction, or stereo-selective reduction and then partial reduction.